Slide 1: Total Heart Intelligence… Wherever You Are
Total Heart Intelligence… Wherever You Are SECOND QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL AUGUST 13, 2026 NASDAQ: BEAT
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and
Slide 3: Agenda
Agenda WHAT WE’LL COVER: ON THE CALL TODAY: HeartBeam’s Core Technology and Platform Q2 2026 and Recent Operational Highlights Heart Attack Detection RICHARD FERRARI DR. BRANISLAV VAJDIC TIM CRUICKSHANK HeartBeam System: Initial Commercial Launch Financials Second Quarter 2026 Financial Results Conf
Slide 4: Every 40 Seconds, Someone in the U.S. Suffers from a Heart Attack
Every 40 Seconds, Someone in the U.S. Suffers from a Heart Attack HeartBeam has developed 3 form factors to address the unmet need, each with a unique approach HeartBeam System On-Demand HeartBeam Remote (Card) 12-Lead Patchi Uniti • Post-discharge monitoring • Extended monitoring with • Remote/rura
Slide 5: HeartBeam's Core Technology and Platform
HeartBeam’s Core Technology and Platform Why HeartBeam Is Fundamentally Different A Decade of IP, One Architecture CARDIAC PLATFORM OPPORTUNITY i • Powered by 25+ issued patents worldwide and $40B incorporating our proprietary TriCor 3D signal reconstruction Clinically-Validated Today Ability to ser
Slide 6: Key Strategic Priorities
Key Strategic Priorities INTEGRATED NETWORK HEART ATTACK DETECTION INITIAL COMMERCIAL LAUNCH PARTNERSHIPS • Rapidly advancing initiatives around • Initial commercial launch • Goal to accelerate adoption and indication expansion underway use of our technology within the integrated networks utilizing
Slide 7: Q2 2026 and Recent Operational Highlights
Q2 2026 and Recent Operational Highlights Second Quarter 2026 Financial Results Conference Call 7
Slide 8: Heart Attack Detection: Accelerating Path to Indication Expansion
Heart Attack Detection: Accelerating Path to Indication Expansion Future indication expansion would unlock a large addressable market of millions of patients at risk ✓ Completed enrollment in less than 4 months, ahead of schedule ALIGN-ACS ✓ Enrolled 134 patients presenting with chest pain in the E.
Slide 9: Q2 2026 and Recent Operational Highlights
Q2 2026 and Recent Operational Highlights Additional R&D, Clinical and Regulatory highlights from the quarter Clinical grade 12-Lead ECG in a patch ➢ Completed working prototype of 12-Lead ECG Patch form factor • First ambulatory patch device designed to aid in detecting Continuous 1-Lead mode match
Slide 10: Commercial Traction
Commercial Traction Real-World Validation in Q2 2026 and To Date Commercially-released product Signed multiple commercial agreements • End-to-end 24/7 reader service, • Covers all 4 target markets: NYC, Dallas, onboarding workflow, and customer South Florida, Southern California success all live • F
Slide 11: What We've Learned
What We’ve Learned Real-World Commercial Validation ECG QUALITY PATIENT PEACE OF MIND PATIENT ENGAGEMENT Clinicians impressed with high quality Patients have indicated their comfort During onboarding, patients are able of synthesized 12-lead ECG data from a in having the same quality of ECG to see t
Slide 12: Physician Perspective: Dr. Ram Dandillaya
Physician Perspective: Dr. Ram Dandillaya “It’s amazing to have a 12-lead device in your pocket. This is what we have been waiting for.”* “I see a lot of patients with complex, layered heart histories. Having a baseline ECG on file with HeartBeam, captured repeatedly from home over months, turns dis
Slide 13: Patient Perspective: Meet Jerry
Patient Perspective: Meet Jerry • 85-year-old heart patient • Air Force veteran • Successful career in global commercial airlines operations • Extensive cardiac history with 8 stents placed • Having HeartBeam allows him to continue to lead an active life with peace of mind, knowing his doctor has ac
Slide 14: Financials
Financials Second Quarter 2026 Financial Results Conference Call 14
Slide 15: Financial Discipline Aligned to Achieving Milestones
Financial Discipline Aligned to Achieving Milestones Net operating cash outflow of $3.3M in Q2 YEAR-OVER-YEAR QUARTERLY CHANGE QUARTER-OVER-QUARTER CHANGE 2026, down 7% from Q1 2026. Quarter Ended June 30, Quarter Ended $ in Thousands 2026i 2025 June 30, 2026i March 31, 2026 Continued financial disc
Slide 16: Reduced Cost Profile Further Extending the Cash Runway
Reduced Cost Profile Further Extending the Cash Runway REPORTED RESULTS Q2 2026 (GAAP) UNDERLYING NET LOSS i Q2 2026 Net Loss* Underlying Net Lossi $5.0M $4.1M ▼ 12% vs. Q1 2026 | ▼ 17% vs. Q2 2025 Net Cash Used in Operating Activities** *Adjusted for Leadership Transition $3.3M ▼ 7% vs. Q1 2026 | ▼
Slide 17: Summary
Summary Executing on a $40B Cardiac Monitoring Platform Opportunity • Proven technology with strong IP and growing body of clinical evidence • Proprietary TriCor technology is the only technology currently cleared that utilizes this unique 3D signal capturing capability in card form factor • Capital
Slide 18: Redefining Cardiac Care Q&A
Company Investor Relations Redefining Tim Cruickshank CFO Chris Tyson Executive Vice President NASDAQ: BEAT Cardiac Care HeartBeam, Inc. ir@heartbeam.com MZ North America Direct: 949-491-8235 Anytime, Anywhere. www.heartbeam.com BEAT@mzgroup.us www.mzgroup.us Q&A MKT-159 v0 FDA-cleared for arrhythmi